Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes

Clinical Breast Cancer

Volumn 9, Issue SUPPL.2, 2009, Pages

  Murphy, Conleth G ^a   Seidman, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Capecitabine; Epothilones; Ixabepilone; Microtubule inhibitors; Vinca alkaloids; Vinflunine

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOXORUBICIN; EPIRUBICIN; EPOTHILONE DERIVATIVE; ERIBULIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; IXABEPILONE; MITOMYCIN C; NAVELBINE; PACLITAXEL; PEMETREXED; TAXANE DERIVATIVE; VINFLUNINE; ANTINEOPLASTIC AGENT; TAXOID;

ABDOMINAL CRAMP; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSPNEA; FATIGUE; FEVER; FLU LIKE SYNDROME; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; ILEUS; INJECTION SITE REACTION; MEDICAL DECISION MAKING; MONOTHERAPY; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PAIN; PERIPHERAL NEUROPATHY; PHLEBITIS; QUALITY OF LIFE; RASH; REVIEW; SENSORY NEUROPATHY; STOMATITIS; THORAX PAIN; THROMBOCYTOPENIA; VOMITING; BREAST TUMOR; FEMALE; PATHOLOGY;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; TAXOIDS;

EID: 70249116460     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.s.006     Document Type: Article

References (65)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-yearsurvival: an overview of the randomized trials. Lancet 2005;365:1687-717.
2. De Laurentiis M, Cancello G, D'Agostino D, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008;26:44-53.
3. Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 2008;8:324-33.
4. Piccart MJ, Raymond E, Aapro M, et al. Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects. Eur J Cancer 1995;31A:S1-10.
5. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93.
6. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001;92:1759-68.
7. Fumoleau P, Largiller R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004;40:536-42.
8. Lee SH, Lee J, Park J, et al. Capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Med Oncol 2004;21:223-31.
9. Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-33.
10. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9.
11. Blum J, Jones S, Buzdar A. Capecitabine (Xeloda) in 162 patients with paclitaxel pretreated MBC; updated results and analysis of dose modifications. Eur J Cancer 2001;37:S190a (abstract 693).
12. Traina TA, Theodoulou M, Feigin K, et al. Phase I study of a novel capecitabine schedule based on the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 2008;26:1797-802.
13. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009;27(15 suppl) :42s (abstract 1005).
14. Smorenburg CH, Bontenbal M, Seynaeve C, et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res Treat 2001;66:83-7.
15. Modi S, Currie VE, Seidman AD, et al. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer 2005;6:55-60.
16. Rha SY, Moon YH, Jeung HC, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 2005;90:215-21.
17. Valerio MR, Cicero G, Armata MG, et al. Gemcitabine (G) in pretreated breast cancer (BC). Proc Am Soc Clin Oncol 2001;20:51b (abstract 1953).
18. Zelek L, Barthier S, Riofro M, et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001;92:2267-72.
19. Udom DI, Vigushin DM, Linardou H, et al. Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimes for advanced breast cancer. Eur J Cancer 2000;36:177-82.
20. Toi M, Saeki T, Aogi K, et al. Late phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn J Clin Oncol 2005;35:310-5.
21. Ibrahim NK, Rahman Z, Valero V, et al. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 1999;86:1251-7.
22. Jara-Sanchez C, Martin M, Garcia-Saenz JA, et al. Vinorelbine as a 96-hour infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group. Clin Breast Cancer 2003;3:399-404.
23. Livingston RB, Ellis GK, Gralow JR, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:1395-400.
24. Martin M, Ruiz A, Munoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007;8:219-25.
25. Saphner T, Weller EA, Tormey DC, et al. 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature. Am J Clin Oncol 2000;23:258-62.
26. Pusztai L, Walters RS, Valero V, et al. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol 1998;21:442-6.
27. Perez EA, Hillman D W, Mailliard JA, et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane or both. J Clin Oncol 2004;22:2849-55.
28. Vukelja S, O'Shaughnessy J, Campos S, et al. Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: phase II study results. J Clin Oncol 2005;23(suppl) :19s (abstract 562).
29. Martin M, Spielmann M, Namer M, et al. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol 2003;14:1246-52.
30. O'Shaughnessy JA, Clark RS, Blum JL, et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 2005;6:143-9.
31. Llombart-Cussac A, Theodoulou M, Rowland K, et al. Pemetrexed in patients with locally advanced or metastatic breast cancer who had received previous anthracycline and taxane treatment: phase II study. Clin Breast Cancer 2006;7:380-5.
32. Chattopadhyay S, Tamari R, Min SH, et al. Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability. Oncologist 2007;12:808-15.
33. Campone M, Cortes-Funes H, Vorobiof D, et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 2006;95:1161-6.
34. Blum JL, Pruitt BT, Fabian CJ, et al. Phase II study of eribulin mesylate (E7389) in patients with heavily pretreated advanced breast cancer. Paper presented at: The 2007 Breast Cancer Symposium: Integrating Emerging Science Into Clinical Practice; September 7-8, 2007; San Francisco, CA. Abstract 223. Available at: http://www.asco.org. Accessed: March 24, 2009.
35. Vahdat LT, Twelves C, Allison MK, et al. Phase II study of eribulin mesylate (E7389) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracycline, taxane, and capecitabine therapy. J Clin Oncol 2008;26(suppl) :62s (abstract 1084).
36. E7389 versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer. ClinicalTrials.gov [Web site]. Available at: http://clinicaltrials.gov/show/NCT00388726. Accessed: February 10, 2009.
37. Seidman AD, Hochhauser D, Gollub M, et al. Ninety-six hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 1996;14:1877-84.
38. Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19:4216-23.
39. Lin YC, Chang HK, Wang CH, et al. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel. Anticancer Drugs 2000;11:617-21.
40. Sawaki M, Ito Y, Hashimoto D, et al. Paclitaxel administered weekly in patients with docetaxel-resistant metastatic breast cancer: a single-center study. Tumori 2004;90:36-9.
41. Valero V, Jones SE, Von Hoff DD, et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16:3362-8.
42. Blum JL, Savin MA, Edelman G, et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007;7:850-6.
43. Rivera E, Valero V, Esteva FJ, et al. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol 2002;49:299-302.
44. Al-Batran SE, Bischoff J, Von Minckwitz G, et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracylines: a multicentre phase II trial. Br J Cancer 2006;94:1615-20.
45. Keller AM, Mennel RG, Vassilis A, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004;22:3893-901.
46. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 2003;8(suppl 2):17-24.
47. Damle BD, Letrent S, Duncan G, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of BMS-247550, an epothilone analog, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:68a (abstract 268).
48. Gadgeel SM, Wozniak A, Boinpally RR, et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res 2005;11:6233-9.
49. Aghajanian C, Burris HA, 3rd, Jones S, et al. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol 2007;25:1082-8.
50. Shimizu T, Yamamoto N, Yamada Y, et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol 2008;61:751-8.
51. Mani S, McDaid H, Hamilton A, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004;10:1289-98.
52. Abraham J, Agrawal M, Bakke S, et al. Phase I trial and pharmacokinetic study of BMS-247750, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003;21:1866-73.
53. Zhuang SH, Agrawal M, Edgerly M, et al. A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer 2005;103:1932-8.
54. Burris HA III, Awada A, Jones S, et al. Phase I study of the novel epothilone BMS-247550 administered weekly in patients (pts) with advanced malignancies. Proc Am Soc Clin Oncol 2002;21:104a (abstract 412).
55. Awada A, Bleiberg H, de Valeriola D, et al. Phase I clinical and pharmacology study of the epothilone B analog BMS-247550 given weekly in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 2001;20:108a (abstract 427).
56. Denduluri N, Lee JJ, Walshe J, et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs 2007;25:63-7.
57. Thomas E, Tabernero J, Fornier M, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399-406.
58. Low JA, Wedam SB, Lee JJ, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 2005;23:2726-34.
59. Denduluri N, Low JA, Lee JJ, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol 2007;25:3421-7.
60. Roché H, Yelle L, Cognetti F, et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415-20.
61. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407-14.
62. Bunnell C, Vahdat L, Schwartzberg L, et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Clin Breast Cancer 2008;8:234-41.
63. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:5210-7.
64. Drugs@FDA. U. S. Food and Drug Administration [Web site]. Available at: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA. Accessed: February 10, 2009.
65. Tchekmedyian NS, Hickman M, Siau J, et al. Treatment of cancer anorexia with megestrol acetate: impact on quality of life. Oncolog y (Williston Park) 1990;4:185-92.